NEW YORK (GenomeWeb) – BioMérieux said today that its first quarter revenues rose 3 percent year over year, driven by an intense flu season and growth in the Asia Pacific region.

BioMérieux also announced today that it has submitted a 510(k) application to the US Food and Drug Administration for its BioFire FilmArray Pneumonia Panel.

For the three months ended March 31, the company reported revenues of €587 million ($726.6 million), up from €568 million in the prior-year period. At a constant exchange rates and scope of consolidation, revenues grew 13 percent year over year.